/CRMD
CRMD Stock - CorMedix Inc.
Healthcare|BiotechnologyNASDAQ
$12.02+0.84%
+$0.10 (+0.84%) • Dec 19
77
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.76
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+83.0%upside
Target: $22.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CRMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.90 – $12.14
TARGET (TP)$22.00
STOP LOSS$11.06
RISK/REWARD1:10.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.32
52W High$17.43
52W Low$5.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $43.47M | N/A | $65,408 | $190,936 | $239,231 |
| Gross Profit | $40.28M | $-205,562 | $61,674 | $41,998 | $34,385 |
| Gross Margin | 92.7% | N/A | 94.3% | 22.0% | 14.4% |
| Operating Income | $-22,356,389 | $-48,957,788 | $-30,623,968 | $-29,437,585 | $-27,220,752 |
| Net Income | $-17,930,020 | $-46,339,227 | $-29,701,705 | $-28,210,226 | $-22,027,683 |
| Net Margin | -41.2% | N/A | -45409.9% | -14774.7% | -9207.7% |
| EPS | $-0.30 | $-0.91 | $-0.74 | $-0.75 | $-0.77 |
Company Overview
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
86%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$14
Average Target
↑ 19.2% Upside
Now
$6
Low
$14
Average
$20
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 20th 2025 | D. Boral Capital | Upgrade | Buy | $14 |
| June 30th 2025 | H.C. Wainwright | Initiation | Buy | $20 |
| June 30th 2025 | D. Boral Capital | Downgrade | Hold | - |
| March 7th 2025 | Leerink Partners | Initiation | Outperform | $18 |
| January 13th 2025 | D. Boral Capital | Initiation | Buy | $15 |
| August 26th 2024 | Rodman & Renshaw | Initiation | Buy | $13 |
| August 10th 2023 | RBC Capital Mkts | Initiation | Outperform | $6 |
Earnings History & Surprises
CRMDBeat Rate
68%
Last 19 quarters
Avg Surprise
+9.9%
EPS vs Estimate
Beats / Misses
13/6
Last 12 quarters
Latest EPS
$0.57
Q4 2025
EPS Surprise History
Q1 24
-23.8%
$-0.26vs$-0.21
Q2 24
+7.4%
$-0.25vs$-0.27
Q3 24
+3.8%
$-0.25vs$-0.26
Q4 24
+50.0%
$-0.05vs$-0.10
Q1 25
+29.4%
$0.22vs$0.17
Q2 25
+20.0%
$0.30vs$0.25
Q3 25
+40.0%
$0.28vs$0.20
Q4 25
+18.7%
$0.57vs$0.48
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 24, 2026 | $0.89 | — | — | — |
Q4 2025 | Nov 12, 2025 | $0.48 | $0.57 | +18.7% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $0.20 | $0.28 | +40.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.25 | $0.30 | +20.0% | ✓ BEAT |
Q1 2025 | Mar 25, 2025 | $0.17 | $0.22 | +29.4% | ✓ BEAT |
Q4 2024 | Oct 30, 2024 | $-0.10 | $-0.05 | +50.0% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.27 | $-0.25 | +7.4% | ✓ BEAT |
Q1 2024 | Mar 12, 2024 | $-0.21 | $-0.26 | -23.8% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-0.21 | $-0.17 | +19.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q1 2023 | Mar 30, 2023 | $-0.19 | $-0.20 | -5.3% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.23 | $-0.17 | +26.1% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.20 | $-0.19 | +5.0% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.23 | $-0.18 | +21.7% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q4 2021 | Nov 9, 2021 | $-0.18 | $-0.22 | -22.2% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.18 | $-0.12 | +33.3% | ✓ BEAT |
Q2 2021 | May 13, 2021 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Latest News
D. Boral Capital Maintains Buy on Cormedix, Maintains $14 Price Target
📈 PositiveBenzinga•Dec 18, 2025, 07:49 PM
CorMedix Announces Interim Results For Ongoing Real-World Evidence Study Being Conducted In Conjunction With USRC's Use Of DefenCath In Adult Hemodialysis Patients With Central Venous Catheters
➖ NeutralBenzinga•Dec 18, 2025, 01:05 PM
HC Wainwright & Co. Maintains Buy on Cormedix, Raises Price Target to $18
📈 PositiveBenzinga•Nov 13, 2025, 12:29 PM
CRMD stock has given up its prior gain. Cormedix shares were trading higher after the company reported Q3 earnings and revenue above estimates and issued FY2025 sales guidance above expectations.
➖ NeutralBenzinga•Nov 12, 2025, 07:43 PM
D. Boral Capital Maintains Buy on Cormedix, Maintains $14 Price Target
📈 PositiveBenzinga•Nov 12, 2025, 07:09 PM
Needham Maintains Buy on Cormedix, Lowers Price Target to $16
📈 PositiveBenzinga•Nov 12, 2025, 07:00 PM
Cormedix shares are trading higher after the company reported Q3 earnings and revenue above estimates and issued FY2025 sales guidance above expectations.
📈 PositiveBenzinga•Nov 12, 2025, 05:30 PM
UPDATE: Cormedix Q3 Adj. EPS $0.57 Misses $0.65 Estimate.
📉 NegativeBenzinga•Nov 12, 2025, 01:55 PM
Cormedix Sees FY2025 Sales $390.000M-$410.000M vs $283.692M Est
📈 PositiveBenzinga•Nov 12, 2025, 12:40 PM
Cormedix Sees Q4 Sales $115.000M-$135.000M vs $118.847M Est
📈 PositiveBenzinga•Nov 12, 2025, 12:40 PM
CorMedix GAAP EPS of $1.26 beats by $0.63, revenue of $104.28M beats by $18.26M
📈 PositiveSeeking Alpha•Nov 12, 2025, 12:32 PM
Cormedix Q3 EPS $1.26 Beats $0.63 Estimate, Sales $104.270M Beat $86.023M Estimate
📈 PositiveBenzinga•Nov 12, 2025, 12:32 PM
CorMedix Says DefenCath Receives Innovative Technology Designation From Vizient
📈 PositiveBenzinga•Oct 23, 2025, 12:32 PM
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $22
📈 PositiveBenzinga•Oct 21, 2025, 02:34 PM
D. Boral Capital Upgrades Cormedix to Buy, Announces $14 Price Target
📈 PositiveBenzinga•Oct 20, 2025, 01:33 PM
Market-Moving News for October 20th
➖ NeutralBenzinga•Oct 20, 2025, 11:36 AM•Also: ,
CorMedix shares are trading higher after the company raised its 2025 pro forma net revenue guidance.
📈 PositiveBenzinga•Oct 20, 2025, 11:33 AM
CorMedix Sees Q3 Unaudited Pro Forma Net Revenue Over $125M; Raises FY 2025 Pro Forma Net Revenue Guidance To $375M+
📈 PositiveBenzinga•Oct 20, 2025, 11:32 AM
CorMedix Files For Offering Of Up To 6.3M Shares Of Common Stock By Selling Securityholders
➖ NeutralBenzinga•Sep 30, 2025, 09:22 PM•Also:
CorMedix Completes Enrollment In Phase III ReSPECT Trial For REZZAYO In Fungal Infection Prevention
📈 PositiveBenzinga•Sep 29, 2025, 01:20 PM
Frequently Asked Questions about CRMD
What is CRMD's current stock price?
CorMedix Inc. (CRMD) is currently trading at $12.02 per share. The stock has moved +0.84% today.
What is the analyst price target for CRMD?
The average analyst price target for CRMD is $22.00, based on 1 analyst.
What sector is CorMedix Inc. in?
CorMedix Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is CRMD's market cap?
CorMedix Inc. has a market capitalization of $0.95 billion, making it a small-cap company.
Does CRMD pay dividends?
No, CorMedix Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABUS
Arbutus Biopharma Corporation
$4.43
Mkt Cap: $0.9B
BCAX
Bicara Therapeutics Inc. Common Stock
$17.60
Mkt Cap: $1.0B
EYPT
EyePoint Pharmaceuticals, Inc.
$17.43
Mkt Cap: $1.2B
KURA
Kura Oncology, Inc.
$9.84
Mkt Cap: $0.9B
NBTX
Nanobiotix S.A.
$22.13
Mkt Cap: $1.1B
PROK
ProKidney Corp.
$2.37
Mkt Cap: $0.3B
PVLA
Palvella Therapeutics, Inc.
$99.73
Mkt Cap: $1.2B
SEPN
Septerna, Inc.
$29.58
Mkt Cap: $1.3B
SVRA
Savara Inc.
$6.05
Mkt Cap: $1.2B
TNGX
Tango Therapeutics, Inc.
$8.52
Mkt Cap: $0.9B
Explore stocks similar to CRMD for comparison